Apexigen has formed eight partnerships with pharmaceutical companies that are advancing a variety of antibodies for the treatment of cancer and inflammatory/autoimmune, ophthalmic and other diseases. Five partnered programs are currently in clinical development with additional programs progressing through preclinical development. Data generated to date from these development programs suggest that APXiMAB™ antibodies make excellent human therapeutic drug candidates with broad applicability over a wide range of diseases. To view the progress of these programs, please see the Pipeline page.


Apexigen is interested in

  • Strategic alliances for the discovery and development of innovative oncology drugs
  • Co-development opportunities for oncology drugs

Contact Mark Nevins, Vice President, Business Development at